Study summary
Adding daratumumab to first treatment tripled complete responses and lengthened survival
59.5%complete blood response, vs 19.2% with VCd alone
What was tested
Daratumumab, an antibody against CD38 on plasma cells, added to bortezomib, cyclophosphamide and dexamethasone (VCd), against VCd alone, for newly diagnosed AL amyloidosis.
What they found
- Complete blood (hematologic) response was 59.5% vs 19.2%.
- After about 5 years, risk of death was 38% lower (hazard ratio 0.62).
- Heart and kidney responses were 2 to 3 times more common.
What it means
Confirms Dara-VCd as the standard first treatment, now with a proven survival benefit.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.